­
­
­
­

Inventi Impact: Nutraceuticals

Articles

  • Inventi:pnc/22540/17
    The Nutraceutical Dehydrozingerone and Its Dimer Counteract Inflammation- and Oxidative\nStress-Induced Dysfunction of In-vitro Cultured Human Endothelial Cells: A Novel Perspective for the Prevention and Therapy of Atherosclerosis
    01-Jan-1970 Research 2017 : April - June
    Elisabetta Profumo, Brigitta Buttari, Daniela Dâ??Arcangelo, Lavinia Tinaburri, Maria Antonietta Dettori, Davide Fabbri, Giovanna Delogu, Rachele Rigano

    Atherosclerosis is characterized by endothelial dysfunction, mainly induced by inflammation and oxidative stress. Increased\nreactive oxygen species (ROS) production together with increased adhesion molecules and thrombogenic tissue factor (TF)\nexpression on endothelial cells has a key role in proatherogenic mechanisms. Therefore downmodulation of these molecules could\nbe useful for reducing the severity of inflammation and atherosclerosis progression. Dehydrozingerone (DHZ) is a nutraceutical\ncompound with anti-inflammatory and antioxidant activities. In this studywe evaluated the ability ofDHZ and its symmetric dimer\nto modulate hydrogen peroxide- (H2O2-) induced ROS production in human umbilical vein endothelial cells (HUVEC). We also\nevaluated intercellular adhesionmolecule- (ICAM-) 1, vascular cell adhesionmolecule- (VCAM-) 1, and TF expression in HUVEC\nactivated by tumor necrosis factor- (TNF-)

    How to Cite this Article
    CC Compliant Citation: Elisabetta Profumo, Brigitta Buttari, Daniela D'Arcangelo, et al., â??The Nutraceutical Dehydrozingerone and Its\nDimer Counteract Inflammation- and Oxidative Stress-Induced Dysfunction of In Vitro Cultured Human Endothelial Cells: A Novel\nPerspective for the Prevention and Therapy of Atherosclerosis,â? Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1246485,\n12 pages, 2016. doi:10.1155/2016/1246485, https://creativecommons.org/licenses/by/4.0/.
    Download Full Text